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Introduction
Malignant melanoma (MM) is accounting for the vast majority of skin cancer death with an increasing incidence. 1 Estimated incidence rates in European countries range between 4.3 and 19.5/100 000 in men and between 5.5 and 25.4/100 000 in women. In 2012, there were approximately 91 500 persons affected including 22 000 deaths caused by MM in Europe. 2 When MM is diagnosed at an early stage it can be effectively treated and patients have a good chance to recover. 3 For patients with advanced stages chances to recover are worse, though in recent years new high-price drugs, all being biological, have been developed, that may prolong survival. [4] [5] [6] The treatment as well as productivity loss due to morbidity or premature mortality are associated with a financial burden to society. Cost-of-illness (COI) studies can be used as a tool to assess this economic burden, to support planning of health services and political decision-making. 7 For skin cancer, the most important information that can be gained from COI are the societal costs. These overall costs are needed to estimate the potential cost-effectiveness of prevention programs by averting cases of (advanced stage) MM.
There are few COI studies on MM in European countries. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] We identified two systematic reviews comparing COI across selected countries. 19, 20 However, COI data are not available for most of the European countries. To our knowledge, there have no data been published which estimate the COI in all European countries or the whole European Union (EU). Therefore, the purpose of this study was to model COI in all EU states and all member states of the European Free Trade Association (EFTA), to present and to compare the COI per patient at the national level and to analyse the distribution of costs by cost categories. Results from our study can be used to estimate the potential of prevention programs with respect to effectiveness and costeffectiveness. It has been shown that the risk of skin cancer can be reduced by improving adherence to sun protection and recommendations on skin cancer prevention. 21, 22 Prevention programs can disseminate these recommendations and knowledge that is essential for preventive behaviour. Moreover, secondary prevention, leading to detection of MM at early stages, can potentially reduce mortality and burden of disease. Accordingly, prevention of skin cancer may not only improve the health status of a population but also reduce COI by decreasing the need for treatment and treatment costs. 23, 24 
Materials and methods
This COI analysis is based on the integration of publicly available economic and epidemiological data from the EU/EFTA countries into a single model. The model thus follows 'best evidence' and is evaluated by sensitivity analysis.
Data sources
Several sources were used to determine the COI of MM. Population data were derived from the World Bank. 25 The epidemiological information on mortality due to MM by age and prevalence of MM for each country in 2012 was taken from the International Agency for Research on Cancer.
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The 1-year prevalence was here defined as the number of persons with MM in 2012 and still alive at the end of the year. We calculated the costs based on the prevalence approach. Morbidity costs were estimated for all patients still alive at the end of 2012. Mortality costs were estimated for all patients who died during this year. Total COI included direct costs, morbidity and mortality costs.
To estimate the treatment costs of MM on a patient's level, a systematic literature research in Medline/PubMed was conducted. Further information on methodology and results of the review are reported elsewhere. 20 The costs in the five included publications were converted into Euro and adjusted for the reference year 2012. If no epidemiological information for 2012 was available for a country, data for the most recent year were taken for analysis.
Additional data sources were used for the economic model on COI:
• Information on the national gross domestic product (GDP) was obtained from the World Bank. 25 • The national health expenditures (HE) were gained from the United Nations Statistics Division (UNSD).
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• Information on the gross national income (GNI) and the income development was taken from the World Bank.
25 Figure 1 Economic model -example for modelling total national treatment costs based on GDP, HE and the GNI. GDP, gross domestic product; GNI, gross national income; HE, health expenditures; p.p., per patient; PPP, purchasing power parity.
Economic model on COI
To estimate COI in the European countries, we conducted several analyses and used a model for imputation of cost data (Fig. 1) . These calculations are based on the assumption of a relationship between direct medical costs of MM on one site and GDP per capita as well as the share of GDP per capita on HE on the other site. This approach has been used in several publications before and is well established. [27] [28] [29] [30] [31] [32] [33] [34] For the indirect costs, a linear relation between absent days from work due to morbidity and the GNI per capita was assumed. For countries in which information on cost per patient was available, we assumed average costs to be applicable for all patients. If more than one study published was found, we calculated un-weighted average costs.
Where no direct costs for the treatment of MM in a country were found in literature, the assumption was made that treatment costs are proportional to the GDP and to the HE per capita calculated as percentage of the national GDP. Direct costs per patient were extrapolated from countries with cost data available to countries with no cost data available based on the GDP as well as based on HE. Where no morbidity costs for MM were found, we assumed morbidity costs to be proportional to the GNI. Indirect costs per patient were extrapolated from countries with cost data available to countries with no cost data available based on the GNI.
For mortality costs, we used the most recent information from 2010 on GNI per capita by sex and age and adjusted it for 2012 by the national income development. To estimate the productivity loss due to premature death in the future, we forecasted the GNI per capita based on the income development of the past 10 years for each country. We calculated productivity loss for all years until the age of 65 based on the age-specific income for every person died due to MM. Finally, mortality costs were discounted at an annual rate of 3%. A reliable comparison of results on an international level was enabled by adjusting all costs for the purchasing power parity (PPP). PPP is used to eliminate differences in price levels between countries. The price levels are harmonised by adjusting the prices for a defined basket of identical goods in several countries so that the quantity of money needed to buy the defined basket of goods is the same. If for instance our basket of goods contains only a 'BigMac', which costs € 4.7 in Sweden (standardised exchange rates were used) and € 2.4 Poland, we can assume that with the same amount of money, we can purchase in Poland almost twice as much compared to Sweden. 35 Finally, we multiplied the prevalence number with the costs per patient for the treatment of MM to estimate COI for the European countries. As an example, modelling of total costs per patient based on GDP and total national costs based on HE adjusted for the PPP are illustrated in Fig. 1 .
The most conservative costing approach, that should be used therefore, was identified to be present in calculations based on publications including all stages of MM. 20 
Sensitivity analysis
We conducted a sensitivity analysis by extrapolation of direct costs based on the GDP per capita as well as on the HE per capita. Most publications transferring direct costs into other countries are based on calculations using the GDP. We conducted also analysis based on national HE because this approach seems to provide the most accurate results. Real direct costs are supposed to be in the cost range resulting from these two approaches.
Results

Characterisation of epidemiology and national economic data
The countries included in this analysis showed huge variations in the population size as well as in the economic performance (Table 1 ). In 2012, Germany as the country with the largest population (80.4 mio.) had 250 times more inhabitants compared to Iceland with about 321 700 inhabitants only. This had a strong impact on the number of annual prevalent cases per country ranging from 43 cases in Malta to 17 610 cases in Germany and therefore on the national costs for MM. The costs per patient as well as the national MM costs were also affected by the economic performance of countries. This can be measured by the GDP per capita (€ 5742-€ 82 069), the HE per capita (€ 425-€ 7314) or the GNI per capita (€ 4768-€ 62 566). Cost-of-illness of melanoma
Direct costs of melanoma
Estimated real direct costs based on the GDP resulted in an average of € 4437 per patient, ranging between € 833 in Bulgaria and € 11 901 in Luxembourg. Considering population and prevalence of MM in Europe, national treatment costs were estimated for each country, based on the GDP (Table 1) . Real direct national expenditures varied between approximately € 107 000 in Malta and € 88.0 million in Germany and summed up to € 406.0 million for all included countries. When these estimates were based on HE, costs per patient were higher with an average amount of € 4521 ranging from € 476 in Romania to € 10 793 in Denmark. National direct costs varied between € 94 000 in Malta and € 95.6 million in Germany. Costs for all member states of the EU and the EFTA states amounted to € 413.6 million.
Morbidity costs of melanoma
Annual costs per patient caused by productivity loss due to morbidity ranged between € 126 in Sweden and € 5472 in the United Kingdom (Table 2 ). In this cost category, national costs were highest in the United Kingdom (€ 80.7 million) and lowest in Malta (€ 45 230). Costs for all countries amounted for € 217.1 million.
Mortality costs of melanoma
The greatest share of COI resulted from the mortality due to MM and its impact on indirect costs. Mortality costs depended on the prevalence of the annual life years lost before the age of 65, which ranged between 35 years in Iceland and 10 585 years in Germany (Table 2) . Therefore, mortality costs per person varied between € 5559 in Bulgaria and € 41 463 in Greece. National mortality costs were lowest in Iceland (€ 837 000) and highest in Germany (€ 407.6 million). For all included countries they summed up to € 2152 million.
Total costs of melanoma
Combining morbidity and mortality costs, total indirect costs per patient ranged from € 5826 in Bulgaria to € 42 852 in Cyprus. National indirect costs varied between € 930 000 in Iceland and € 448 million in Germany. Indirect costs for all included countries amounted for € 2369 million with mortality costs accounting for 90% of indirect costs.
Total COI of MM including direct and indirect costs resulted in € 2775 million to € 2783 million for all included countries. Lowest costs were found in Iceland (€ 1.1 million) and highest in Germany (€ 543.8 million). COI per patient amounted to approximately € 30 000 on average and were lowest in Bulgaria (€ 6422) and highest in Luxembourg (€ 50 734).
On average, expenditures for treatment amounted for 12-14% of total COI. Here, major differences existed between countries: while direct costs made up 14-26% of total costs in most northern and central European countries, they accounted for 3-12% in most eastern European countries. (Fig. 2) .
International comparison of adjusted COI for melanoma
Using the health basket to adjust the price levels, average annual direct costs amounted to € 4300 per patient on average and are therefore higher compared to adjustment using the GDP (Fig. 3) . Annual costs per patient ranged between countries from € 534 in Poland to € 8939 in Portugal. Total average costs per patient amounted for € 29 689 per patient and are therefore similar to calculations based on the GDP. Here, lowest costs were also found in Bulgaria (€ 14 420) and highest in Cyprus (€ 50 150).
Despite the reduction of cost differences between countries by PPP-adjustment, huge international divergences remained when comparing expenditures per patient. In most countries, estimated costs by the GDP and HE were comparable (AE10%). However, for Luxembourg, the Baltic States, Poland, the Czech Republic, Croatia, Romania and Cyprus estimations based on the GDP exceeded estimations based on HE for 34-100%. These countries spent a significant smaller amount of their GDP for health (5.8-7.1%) compared to the rest of EU and EFTA members (7.4-11.0%).
Regardless if these cost calculations were based on the GDP or the HE, we found much lower treatment expenses for countries that entered the EU since the year 2004, in particular countries in the east and southeast of Europe. This also counted for indirect costs due to morbidity but not for mortality costs. Here highest costs were reached in Greece and Cyprus -both countries with a number of 1.8 life years lost before the age of retirement per patient. Additionally we found a significant correlation (P = 0.001) between GDP per capita and the share of direct costs in total COI (GDP: r = 0.3473; HE r = 0.3387): the higher the GDP per capita, the higher the share of direct costs in total COI of MM. The GDP per capita explained 34% of variance in the share of direct costs in total COI calculated (Fig. 4) .
International comparison of melanoma COI on a national level
For the calculation of national treatment costs beside the costs per patient and the mortality, additionally the population size and the prevalence have to be taken into account. Cost-of-illness of melanoma As expected, COI was highest in countries with a large population. The highest national costs varied from € 139.8 million in Spain to € 517.0 million in the Germany (Table 3) . Accordingly, lowest national costs were found in countries with a small population ranging from € 1.1 million in Iceland to € 6.0 million in Latvia, despite of relative high costs per patient (Figs 2 and 3) .
For all countries, only marginal differences in COI existed between calculations based on the GDP and the HE. However, for ten of the 13 new associated countries direct costs based on the HE were more than 25% lower compared to the calculations based on the GDP.
Discussion
Although many publications have issued the disease burden and costs of MM, very few studies have provided comparative data for the whole number of EU and EFTA states. A major reason for this is the lack of data for many countries, both with respect to direct and indirect costs as well as epidemiology of MM. For this, the current project was started in order to gain an overall set of cost data for MM in all these countries based on an interpolation model. The data are to be used for a better understanding of economic disease burden from MM, for health policy purposes and for the conductance of cost-effectiveness analyses on preventive programs.
We used the GDP and the HE to estimate the direct costs in our model. Several publications have shown a close relation between GDP and expenditures of certain diseases. Similar approaches were made for estimation of health-economic burden of other diseases like diabetes, dementia, dental diseases, disorders of the brain and HIV infections. 27, 32, 34, [36] [37] [38] [39] [40] Indirect costs due to morbidity and mortality were estimated by the GNI using the methodology published in several articles. 27, 33, 34, 37, 38 We identified two systematic reviews comparing international COI of MM. 19, 20 Here, publications on national COI were compared without estimations concerning countries with no cost information available. To our knowledge, the current publication is the first in which MM costs are modelled and compared for European countries. Before and also after adjustment for the PPP there were marked differences in costs per person between the northern and western countries on the one site and the eastern and southern countries on the other site. These differences can also be seen between the old member states of the EU/EFTA and countries that joined the EU since 2004:
• Even after adjusting for the PPP which reduced differences between countries costs were higher in the northern and western/old member states. For instance, costs in Luxembourg exceeded costs in Bulgaria by eight times.
• In the northern and western countries or the old member states, the share of direct costs in total costs was significantly higher. There were several reasons for these differences. In most of the eastern and southern states and countries that joined the EU since 2004:
• The GDP was lower.
• The share of GDP spend on medical care was lower.
• The mortality due to MM in a younger age was higher.
Mortality at young age leads to a high number of life years lost before retirement. In the new member states of the EU, there were on average 1.03-1.98 years per patient lost at working age causing high indirect costs. In contrast, in the rest of the considered countries each MM patient lost 0.41-0.94 life years on average before reaching the age of 65 years.
Cost-of-illness on the national level additionally depends on the population size and the prevalence number. In combination, these variables can mutually reinforce each other. Therefore, countries with high costs per patient (for instance Luxembourg) resulted in comparatively low national costs while countries with average costs per patient (for instance Germany) resulted in extremely high national cost due to their population size.
Costs per inhabitant tended to be also lower in the new member states ranging from € 1.1 in Bulgaria to € 7.12 in Slovenia after adjusting for PPP. In the older member states, COI accounted for € 2.6 to € 11.5 per inhabitant with lowest costs in the southern countries like Portugal, Greece and Spain.
We found a prevalence of 91 500 persons in 2012 affected by MM in the included countries with COI accounting for a total of approximately € 2.7 billion which shows a potential for effective prevention programs as well as a potential for these programs to be cost-effective. The potential cost-effectiveness could be even higher since we tend to underestimate the COI due to malignant MM as the direct costs used in the model accrued in the years 2000-2008 when less expensive drugs were available. The highest potential for prevention programs is located in countries with the most life years lost at young ages or high treatment costs. The decision to focus on either primary or secondary prevention should be made on a national level based on the awareness in the population already existing.
Limitations
There are several potential causes for bias in the analysis of claim data in general, which cannot be ruled out in this study. A risk of bias consists in the false-positive documentation of MM patients and the persisting use of codes after healing which affects prevalence. On the other side, studies based on cancer registry data may miss MM patients due to underreporting and thus underestimate the occurrence of tumours.
In incremental cost studies, the difference between costs in the general population and in patients with MM can arise from other diseases than MM.
Some limitations result also from the methodology of modelling. Comparison of outcomes from various studies is challenging due to:
• Different time horizons, • Different approaches (prevalence vs. incidence and topdown vs. bottom-up),
• Different costs included (hospitalisation, outpatient visits, drugs, direct and indirect costs) and Figure 4 Gross domestic product per (GDP) capita and share of direct costs in total cost-of-illness (COI). AT, Austria; BE, Belgium; BG, Bulgaria; CH, Switzerland; CY, Cyprus; CZ, Czech Republic; DE, Germany; DK, Denmark; EE, Estonia; EL, Greece; ES, Spain; FI, Finland; FR, France; HR, Croatia; HU, Hungary; IE, Ireland; IS, Iceland; IT, Italy; LT, Lithuania; LU, Luxembourg; LV, Latvia; MT, Malta; NL, The Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; SE, Sweden; SI, Slovenia; SK, Slovakia; UK, United Kingdom. GDP, gross domestic product; GNI, gross national income; HE, health expenditures; p.p., per patient; PPP, purchasing power parity.
• Different entities (units, cases, persons).
The comparison of outcomes across different countries is additionally challenging due to different currencies, different health system structures, deviating legal requirements considering registration of skin cancer cases and complex interrelations of influencing factors.
All of the included publications distinguish between the origins of costs, for instance expenditures for drugs, hospitalisation or outpatient treatment. Such distinction was also made in some articles comparing national treatment cost across countries. 27, 33, 34 Due to varying national proportions in the origins of expenditures arising from differences in the structure of the health care systems and due to different classifications of costs in the included publications we decided to forge such a distinction. 41, 42 We know for instance Drug-spending amount for 7.6% of total HE in Switzerland and for 27.8% in Hungary, Spending for inpatient treatment amount for 22.5% of total HE in Portugal and for 47.6% in Switzerland, Spending for outpatient treatment amount for 18.2% of total HE in Norway and for 48.9% in Sweden, but it remains unclear if this is also true in MM.
For the mortality costs, we consider persons that died before the age of retirement. However, for morbidity no information about the age of affected persons was available at a national level. Therefore, we calculated morbidity costs for all persons, independently of age.
Finally, we did not distinguish between stages of MM. Some publications focus on certain stages of MM or analyse different stages separately. 8, 12, 13 While treatment costs rise exponentially with the stage of MM, taking the distribution of MM stages within countries into account could increase the accuracy of our model. Since no information on the stages of MM in countries without cost data was available, we chose not to model costs for different stages separately but to combine all stages in one model. Therefore, potential differences in MM stages between countries could not been considered. Since publication of the included articles, new treatment options, in particularly costly drugs, were approved in Europe. Therefore, treatment costs of MM in Europe may be expected to be risen in the last few years.
